Clinical Trial · NCT05436093

CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors

Overview

The objective of the study is to construct a noninvasive approach 68Ga-ACN376 PET/CT to detect the CLDN18.2 expression of tumor lesions in patients with Solid tumors and to identify patients benefiting from CLDN18.2 targeting treatment.

Sponsor

Peking University Cancer Hospital & Institute

Phase

N/A

Contacts

Hua Zhu (CONTACT)

zhuhuabch@pku.edu.cn

010-88196495

Hua Zhu (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT05436093

Drug / Compound

FDG

Isotope(s):

Target(s):

Glucose Transport

Ligand Class: Small Molecules

ACN376

Isotope(s):

Target(s):

Claudin 18.2

Ligand Class: Small Proteins and Antibody Fragments

Eligibility

Inclusion

* 1\. Aged \>18 years old; ECOG 0 or 1;
3\. Has at least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST V1.1);
4\. life expectancy \>=12 weeks.
2\. Patients with solid tumors;

Exclusion

* 1\. Significant hepatic or renal dysfunction;
5\. Suffering from claustrophobia or other mental diseases;
4\. Refusal to join the clinical study;
2\. Is pregnant or ready to pregnant;
3\. Cannot keep their states for half an hour;